celecoxib plus lidocaine
PreclinicalSmall molecule
celecoxib plus lidocaine is one of 12 small molecule programs targeting Pain Control. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Pain Control
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
Tylenol
KKenvue Brands
Approved
Neurontin
VViatris Specialty LLC
Approved
Toradol
JJavelin Pharmaceuticals
Phase 3
Journavx
Vertex PharmaceuticalsPhase 3
Oxycontin
PProtega
Phase 3
Robaxin
GGrupo Espanol de Tumores Neuroendocrinos
Approved
MS Contin
HHikma Pharmaceuticals LLC
Phase 3
Hydrocodone/acetaminophen
AbbViePhase 3
Naproxen Sodium
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pain Control1 trial
Lidocaine Spray Plus Oral Celecoxib for Pain Control During Hysterosalpingography
Completed·—·N/A·NCT04505657·150 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for celecoxib plus lidocaine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- AAswan University Hospital